Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Methods of treating atypical hemolytic uremic syndrome with anti-C5 antibodies

Methods of treating atypical hemolytic uremic syndrome with anti-C5 antibodies

US Patent 10227400 · Granted Mar 12, 2019

Estimated economic value: $220,699,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Monovalent anti-properdin antibodies and antibody fragments2025
Monovalent anti-properdin antibodies and antibody fragments2025
Dynamic valuation systems and methods2025
Subcutaneous dosage and administration of anti-C5 antibodies for treatment of pa2025
Polypeptides that bind complement component C5 or serum albumin and fusion prote2025
Polypeptides that bind complement component C5 or serum albumin and fusion prote2025
Method of quantitating unbound C5 in a sample2024
Humanized anti-CD200 antibodies and uses thereof2023
Dynamic valuation systems and methods2023
Polypeptides that bind complement component C5 or serum albumin and fusion prote2022
Polypeptides that bind complement component C5 or serum albumin and fusion prote2022
Anti-C5 antibodies having improved pharmacokinetics2022